Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 23Lymphoma, Non-Hodgkin 18Leukemia, Myeloid, Acute 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lung Neoplasms 15Leukemia 13Carcinoma, Non-Small-Cell Lung 13Burkitt Lymphoma 13Recurrence 9Multiple Myeloma 9Lymphoma, Follicular 8Hodgkin Disease 8Leukemia, Lymphocytic, Chronic, B-Cell 7Congenital Abnormalities 7Lymphoma, B-Cell 6Sarcoma 5Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasms, Plasma Cell 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Lung Small Cell Carcinoma × Etoposide × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡